Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.

@article{Long2017LongtermIO,
  title={Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.},
  author={B. Long and T. Tompkins and C. Decker and L. Jesaitis and Shahid Khan and P. Slasor and P. Harmatz and C. O’Neill and B. Schweighardt},
  journal={Clinical therapeutics},
  year={2017},
  volume={39 1},
  pages={
          118-129.e3
        }
}
PURPOSE Elosulfase alfa is an enzyme replacement therapy for the treatment of Morquio A syndrome (mucopolysaccharidosis IVA), a lysosomal storage disorder caused by a deficiency of the enzyme N-acetylgalactose-amine-6-sulfatase. We previously reported immunogenicity data from our 24-week placebo-controlled Phase III study, MOR-004. Here, we report the long-term immunogenicity profile of elosulfase alfa from MOR-005, the Phase III extension trial to assess potential correlations between antidrug… Expand
17 Citations

Paper Mentions

Interventional Clinical Trial
This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis… Expand
ConditionsMorquio A Syndrome, MPS IVA, Mucopolysaccharidosis IV A
InterventionDrug
Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future
Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments
Proteomic Analysis in Morquio A Cells Treated with Immobilized Enzymatic Replacement Therapy on Nanostructured Lipid Systems
Enzyme replacement therapy: efficacy and limitations
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
...
1
2
3
...